{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:40:36Z","timestamp":1793090436922,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105610","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:41:19Z","timestamp":1789882879000},"page":"105610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CRISPR and gene editing approaches in prostate cancer: Clinical applications and therapeutic potential"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-338X","authenticated-orcid":false,"given":"Vaibhavkumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratichi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sthiti Porna","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rica","family":"Langstang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105610_bib1","article-title":"Data from a genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer","author":"Abdulkadir","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105610_bib2","series-title":"Prostate Cancer: Molecular Events and Therapeutic Modalities","first-page":"257","article-title":"Gene therapy as a new emerging strategy for prostate cancer","author":"Adelian","year":"2024"},{"issue":"6230","key":"10.1016\/j.critrevonc.2026.105610_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1126\/science.aab1028","article-title":"A prudent path forward for genomic engineering and germline gene modification","volume":"348","author":"Baltimore","year":"2015","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.critrevonc.2026.105610_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1126\/science.aab1028","article-title":"A prudent path forward for genomic engineering and germline gene modification","volume":"348","author":"Baltimore","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105610_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/gt.2009.135","article-title":"Integrase-defective lentiviral vectors: progress and applications","volume":"17","author":"Banasik","year":"2010","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105610_bib6","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1007\/s11033-019-05093-y","article-title":"Evaluation of the CRISPR\/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3","volume":"46","author":"Bat\u0131r","year":"2019","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105610_bib7","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105610_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells14221769","article-title":"CRISPR as a Tool to Uncover Gene Function in Polycystic Ovary Syndrome: A Literature Review of Experimental Models Targeting Ovarian and Metabolic Genes","volume":"14","author":"Bucheeri","year":"2025","journal-title":"Cells"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105610_bib9","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.3390\/cancers14184381","article-title":"vivo application of CRISPR\/Cas9 revealed implication of Foxa1 and Foxp1 in prostate cancer proliferation and epithelial plasticity","volume":"14","author":"Cai","year":"2022","journal-title":"Cancers"},{"issue":"12_","key":"10.1016\/j.critrevonc.2026.105610_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1538-7445.AM2022-924","article-title":"Abstract 924: Modelling the metastatic castration-resistant prostate cancer in mice by orthotopic delivering multiplexed gRNAs of CRISPR\/Cas9 based on AAV system","volume":"82","author":"Cai","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib11","first-page":"2489","article-title":"CRISPR\/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam\/Cabs1 gene cluster expression","volume":"15","author":"Cai","year":"2024","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105610_bib12","doi-asserted-by":"crossref","first-page":"14847","DOI":"10.3390\/ijms241914847","article-title":"The effect of gene editing by CRISPR-Cas9 of miR-21 and the indirect target MMP9 in metastatic prostate cancer","volume":"24","author":"Camargo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6611","key":"10.1016\/j.critrevonc.2026.105610_bib13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105610_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105610_bib15","article-title":"Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer","author":"Chesner","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105610_bib16","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105610_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105610_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/d41586-019-00673-1","article-title":"The CRISPR-baby scandal: What\u2019s next for human gene-editing","volume":"566","author":"Cyranoski","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1089\/crispr.2022.0051","article-title":"Advances in CRISPR Delivery Methods: Perspectives and Challenges","volume":"5","author":"Demirci","year":"2022","journal-title":"CRISPR J."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105610_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI123557","article-title":"Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105610_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105610_bib22","article-title":"CRISPR-Cas9-loaded theranostic liposomes for enhancing radiosensitization of prostate cancer through POLD4 gene editing under real-time MRI monitoring","volume":"13","author":"Fan","year":"2026","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105610_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41391-024-00825-z","article-title":"Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer: clinical","volume":"28","author":"Fang","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105610_bib24","doi-asserted-by":"crossref","first-page":"E5207","DOI":"10.1073\/pnas.1617467114","article-title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing","volume":"114","author":"Fei","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105610_bib25","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.ymthe.2024.09.011","article-title":"Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing","volume":"32","author":"Fieni","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105610_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-024-01310-2","article-title":"Immunoliposome-based targeted delivery of the CRISPR\/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival","author":"Fieni","year":"2024","journal-title":"Exp. & Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105610_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2024.09.011","article-title":"Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing","author":"Fieni","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105610_bib28","article-title":"CRISPR\/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer","author":"Fracassi","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105610_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105610_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105610_bib31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105610_bib33","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1038\/s41467-023-40701-3","article-title":"One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids","volume":"14","author":"Geurts","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105610_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.molmed.2013.02.002","article-title":"Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?","volume":"19","author":"Guo","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib35","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ymthe.2025.03.062","article-title":"Four decades of adenovirus gene transfer vectors: History and current use","volume":"33","author":"Hackett","year":"2025","journal-title":"Mol. Ther. 7"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105610_bib36","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","article-title":"High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities","volume":"163","author":"Hart","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105610_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.gde.2021.08.006","article-title":"Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics","volume":"71","author":"Hayward","year":"2021","journal-title":"Curr. Opin. Genet. & Dev."},{"key":"10.1016\/j.critrevonc.2026.105610_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s44222-025-00277-7","article-title":"Extracellular vesicles for the delivery of gene therapy","volume":"3","author":"Ianni","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.critrevonc.2026.105610_bib39","article-title":"CRISPR\/Cas9 vermittelte TMPRSS2:ERG Genfusion in Prostatakarzinomzellen [Abstract]","author":"Jan","year":"2025","journal-title":"GMS Onkol. Rehabil. Nachsorge"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib40","first-page":"341","article-title":"Epigenetics in prostate cancer treatment","volume":"27","author":"Jones","year":"2021","journal-title":"J. Transl. Genet. Genom."},{"issue":"7873","key":"10.1016\/j.critrevonc.2026.105610_bib41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302264","article-title":"CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds","volume":"19","author":"Kadry","year":"2024","journal-title":"Plos. One"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cell.2014.08.017","article-title":"Identification of multipotent luminal progenitor cells in human prostate organoid cultures","volume":"159","author":"Karthaus","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cell.2014.08.017","article-title":"Identification of multipotent luminal progenitor cells in human prostate organoid cultures","volume":"159","author":"Karthaus","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245349","article-title":"CRISPR\/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells","volume":"16","author":"Khaled","year":"2021","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105610_bib46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105610_bib47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6320","key":"10.1016\/j.critrevonc.2026.105610_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-022-01550-8","article-title":"Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy","volume":"21","author":"Lan","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105610_bib50","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41419-021-04027-6","article-title":"CRISPR screening identifies CDK12 as a conserved vulnerability of prostate cancer","volume":"12","author":"Lei","year":"2021","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105610_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-025-02388-8","article-title":"Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer","author":"Li","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2026.105610_bib52","article-title":"Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer","author":"Li","year":"2026","journal-title":"Genes. Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-022-01561-5","article-title":"Reprogramming the tumor microenvironment by genome editing for precision cancer therapy","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105610_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-023-01738-6","article-title":"Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105610_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"26","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105610_bib56","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2026.105610_bib57","article-title":"Genome editing and cancer: How far has research moved forward on CRISPR\/Cas9?","volume":"153","author":"Mitra","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105610_bib58","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","article-title":"CRISPR\/Cas9 and CAR-T cell: collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment","volume":"79","author":"Mollanoori","year":"2018","journal-title":"Human. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105610_bib59","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjugate Chem."},{"issue":"6320","key":"10.1016\/j.critrevonc.2026.105610_bib60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105610_bib61","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1172\/JCI45109","article-title":"Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts","volume":"121","author":"Ni","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105610_bib62","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1007\/s00210-024-03480-2","article-title":"CRISPR\/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer","volume":"398","author":"Noruzi","year":"2025","journal-title":"Naunyn-Schmiede 's. Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib63","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/15592294.2021.1939477","article-title":"Epigenetic editing in prostate cancer: Challenges and opportunities","volume":"17","author":"Pacheco","year":"2022","journal-title":"Epigenetics"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib64","first-page":"610","article-title":"CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer","volume":"22","author":"Palit","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105610_bib65","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47430","article-title":"TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth","volume":"8","author":"Palit","year":"2019","journal-title":"eLife"},{"issue":"12_Suppl","key":"10.1016\/j.critrevonc.2026.105610_bib66","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1158\/1538-7445.AM2025-6695","article-title":"Abstract 6695: Lipid nanoparticles with cell specific CRISPR activity against cancer","volume":"85","author":"Richardson","year":"2025","journal-title":"Cancer Res."},{"issue":"134","key":"10.1016\/j.critrevonc.2026.105610_bib67","first-page":"57525","article-title":"Virus delivery of CRISPR guides to the murine prostate for gene alteration","author":"Riedel","year":"2018","journal-title":"J. Vis. Exp."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105610_bib68","first-page":"2240","article-title":"vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun","volume":"40","author":"Riedel","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105610_bib69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/10985549.2024.2401465","article-title":"A Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer","volume":"44","author":"Roes","year":"2024","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105610_bib70","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/bit.27882","article-title":"Strengthening the CAR-T cell therapeutic application using CRISPR\/Cas9 technology","volume":"118","author":"Sadeqi Nezhad","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.critrevonc.2026.105610_bib71","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: An update","author":"Schafer","year":"2024","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105610_bib72","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6166","key":"10.1016\/j.critrevonc.2026.105610_bib73","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib74","first-page":"7","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105610_bib75","unstructured":"Smith R.M. Whole Genome CRISPR Screens to Uncover Resistance\/Sensitization Mechanisms Using PSMAxCD3 T Cell Redirection Therapy for the Treatment of Prostate Cancer (Doctoral dissertation, Saint Joseph's University)."},{"key":"10.1016\/j.critrevonc.2026.105610_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1444437","article-title":"Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles","volume":"15","author":"Song","year":"2024","journal-title":"Front. Immunol."},{"issue":"6481","key":"10.1016\/j.critrevonc.2026.105610_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"6481","key":"10.1016\/j.critrevonc.2026.105610_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib79","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12964-024-01833-1","article-title":"Targeting mRNA-coding genes in prostate cancer using CRISPR\/Cas9 technology with a special focus on androgen receptor signaling","volume":"22","author":"Tabibian","year":"2024","journal-title":"Cell. Commun. Signal."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105610_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110417","article-title":"A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer","volume":"38","author":"Tang","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105610_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/cas.70194","article-title":"Development of a synthetic lethality-based combination therapy using LIG1 and PARP inhibitors for prostate cancer","author":"Tani","year":"2025","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105610_bib83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"issue":"6166","key":"10.1016\/j.critrevonc.2026.105610_bib84","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.1246981","article-title":"Genetic screens in human cells using the CRISPR-Cas9 system","volume":"343","author":"Wang","year":"2014","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105610_bib85","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","article-title":"Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR\/Cas-based genome editing","volume":"14","author":"Wei","year":"2020","journal-title":"ACS Nano"},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105610_bib86","first-page":"3845","article-title":"Disassembly of \u03b16\u03b24-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions","volume":"41","author":"Wenta","year":"2022","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105610_bib87","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/104303401300042483","article-title":"Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter","volume":"12","author":"Xie","year":"2001","journal-title":"Human. Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105610_bib88","article-title":"PTEN deficiency impairs IL-15-dependent T-cell immunity against prostate cancer","volume":"726","author":"Xing","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105610_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.676021","article-title":"Using CRISPRa and CRISPRi technologies to study the biological functions of ITGB5, TIMP1, and TMEM176B in prostate cancer cells","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105610_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.676021","article-title":"Using CRISPRa and CRISPRi technologies to study the biological functions of ITGB5, TIMP1, and TMEM176B in prostate cancer cells","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s11658-023-00508-y","article-title":"Synthetic CRISPR\/dCas9-KRAB system driven by specific PSA promoter suppresses malignant biological behavior of prostate cancer cells through negative feedback inhibition of PSA expression","volume":"28","author":"Yang","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymthe.2025.09.045","article-title":"Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells","volume":"34","author":"Ye","year":"2026","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105610_bib93","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1186\/1471-2407-14-808","article-title":"RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization","volume":"14","author":"Young","year":"2014","journal-title":"BMC Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600497X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600497X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:05:53Z","timestamp":1793088353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600497X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":93,"alternative-id":["S104084282600497X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105610","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR and gene editing approaches in prostate cancer: Clinical applications and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105610"}}